Calyxo
CA - PleasantonBiotechnology
Focus: Calyxo is a medical device company focused on kidney stone removal, with its flagship CVAC System having treated over 40,000 patients. The company is actively expanding its clinical evidence and commercial footprint in the urology space.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
32
Should You Work at Calyxo?
AI assessmentBest fit for professionals seeking early-to-mid stage device company growth with strong recent funding, but with higher execution risk than established players.
Why Work Here
- Recent $40M Series F funding (April 2026) signals strong investor confidence and runway for growth initiatives
- Largest clinical evidence presence at AUA 2026 indicates momentum in clinical validation and market traction
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SURE
Kidney StoneClinical Trials (1)
NCT04519294Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)
N/AHelp build intelligence for Calyxo
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.